DelMar Pharmaceuticals Information

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) is a biopharmaceutical company focused on developing and commercializing new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The company’s clinical stage program, VAL-083, is a first-in-class small-molecule chemotherapeutic that has been extensively studied by the U.S. National Cancer Institute and is approved in China for the treatment of lung cancer and chronic myelogenous leukemia. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types, including glioblastoma multiforme (GBM), non-small cell lung cancer (NSCLC) and other solid tumors. DelMar is currently conducting clinical trials in the U.S. with VAL-083 for the treatment of refractory GBM. DelMar’s research demonstrates that VAL-083 exhibits its anti-tumor activity via a novel mechanism of action that could provide improved treatment options for patients whose tumors exhibit phenotypes that are unlikely to respond to currently available therapy.